{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"12"}]}],"title":"QTcF interval increase < 30 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"4"}]}],"title":"QTcF interval increase: 30 to < 60 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"}]}],"title":"QTcF interval increase >= 60 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"8"}]}],"title":"Maximum QTcF interval < 450 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"4"}]}],"title":"Maximum QTcF interval: 450 to < 480 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}]}],"title":"Maximum QTcF interval: 480 to < 500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"}]}],"title":"Maximum QTcF interval >= 500 msec"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"description":"Maximum absolute values and increases from baseline were summarized for QTcF interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula). Number of participants with QTcF meeting the following criteria is presented:QTcF interval:\\<450 msec; QTcF interval: 450 to \\<480 msec; QTcF interval: 480 to \\<500 msec; QTcF interval \\>=500 msec; QTcF interval increase from baseline: \\<30 msec; QTcF interval increase from baseline: 30 to \\<60 msec; QTcF interval increase from baseline \\>=60 msec. End of treatment in the time frame were defined as: maximum of 12 cycles from start of therapy or until disease progression or relapse, participant refusal or unacceptable toxicity occurred, whichever came first.","groups":[{"description":"Participants received 1-2 cycles of induction (glasdegib and daunorubicin/cytarabine), followed by 2-4 cycles of consolidation (glasdegib and high dose cytarabine) and a maximum of 6 cycles of maintenance (glasdegib alone). Daunorubicin was given on Days 1-3 QD at a dose of 60 mg/m\\^2/day by IV together with cytarabine on Days 1-7 at a dose of 100 mg/m\\^2/day by continuous IV infusion for each cycle of induction. Cytarabine was given on Days 1, 3, and 5 at a dose of 1 g/m\\^2 administered as a 3-hour IV infusion every 12 hours (2 g/m\\^2/day) for each cycle of consolidation. Glasdegib tablets 100 mg QD was started on induction Cycle 1/Day -3 and administered continuously QD thereafter for the duration of the study. A cycle was defined as 28 days.","id":"OG000","title":"Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin"},{"description":"Participants received oral doses of glasdegib tablets 100 mg QD in 28-day cycles on a continuous basis, starting on Day 1 of Cycle 1. LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28 day cycles.","id":"OG001","title":"Phase 2 Unfit: Glasdegib 100 mg + LDAC"},{"description":"Participants received LDAC subcutaneously at a dose of 20 mg BID on Days 1-10 of the 28 day cycles.","id":"OG002","title":"Phase 2 Unfit: LDAC Alone"}],"paramType":"NUMBER","populationDescription":"QTc analysis set: all participants enrolled in the study having at least 1 ECG assessment after receiving at least 1 dose of glasdegib.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 2 Fit and Unfit","type":"SECONDARY","unitOfMeasure":"Participants"}